Accretion/Dilution Analysis

Accretion/dilution analysis starts with the acquirer's standalone EPS forecast and then recalculates it after incorporating the financial impact of the target company's earnings, the cost of financing the deal (whether through debt, equity, or cash on hand), and any synergies expected to be realized. If the combined entity's pro forma EPS exceeds the acquirer's standalone forecast, the deal is accretive; if it falls short, the deal is dilutive.

The analysis is mechanically straightforward but conceptually nuanced. Stock-funded acquisitions are dilutive by definition if the acquirer's P/E multiple is lower than the price paid for the target, and accretive if the acquirer trades at a higher multiple than the target's implied P/E. Cash-funded acquisitions avoid share count dilution but introduce interest expense on new debt, which reduces earnings. Deals funded at low interest rates — as was common in the 2010s — could be accretive even at relatively high purchase prices because the after-tax cost of debt was modest relative to the acquired earnings stream.

Synergies are a critical and often contested component of the analysis. Acquirers routinely justify dilutive transactions by projecting cost synergies — headcount reduction, facility consolidation, procurement savings — that will make the deal accretive within two to three years. The credibility of these synergy estimates varies widely. Academic research on merger outcomes in U.S. public company transactions has found that announced synergy targets are frequently not achieved in full, and that acquiring company shareholders often experience negative total returns in the years following large acquisitions.

For investors evaluating a proposed deal, accretion/dilution analysis provides one useful but limited data point. A highly dilutive transaction might still create long-term value if it secures a critical strategic asset; an accretive transaction funded with cheap debt might destroy value if the underlying business deteriorates.